One study assessing the SGLT2 inhibitor dapagliflozin reported a lower incidence of T2DM (hazard ratio 0.53; 95% CI 0.36, 0.77) (Supplementary Table S3). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.